Marianne Abifadel

List of Publications by Year
in descending order

33 papers	6,008 citations	279798 23 h-index	395702 33 g-index
34 all docs	34 docs citations	34 times ranked	6457 citing authors

#	Article	IF	Citations
1	Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren. Metabolites, 2022, 12, 504.	2.9	1
2	Pathogenic variants in THSD4, encoding the ADAMTS-like 6 protein, predispose to inherited thoracic aortic aneurysm. Genetics in Medicine, 2021, 23, 111-122.	2.4	25
3	Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk. Atherosclerosis, 2021, 324, 1-8.	0.8	3
4	Dietary Patterns and Risk Factors of Frailty in Lebanese Older Adults. Nutrients, 2021, 13, 2188.	4.1	6
5	Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. Metabolites, 2021, 11, 564.	2.9	5
6	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. Scientific Reports, 2018, 8, 1943.	3.3	25
7	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
8	Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1. Journal of Clinical Lipidology, 2018, 12, 1374-1382.	1.5	6
9	Plasma proproteinâ€convertaseâ€subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 943-953.	4.4	17
10	The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Pharmacological Reviews, 2017, 69, 33-52.	16.0	90
11	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. Current Atherosclerosis Reports, 2017, 19, 49.	4.8	31
12	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 1377-1392.	5.0	23
13	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
14	Dyslipidaemia in the Middle East: Current status and a call for action. Atherosclerosis, 2016, 252, 182-187.	0.8	37
15	Familial hypercholesterolemia mutations in the Middle Eastern and North African region: A need for a national registry. Journal of Clinical Lipidology, 2015, 9, 187-194.	1.5	44
16	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circulation: Cardiovascular Genetics, 2015, 8, 823-831.	5.1	90
17	Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015, 243, 257-259.	0.8	148
18	PCSK9 polymorphism in a Tunisian cohort: Identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk. Molecular and Cellular Probes, 2015, 29, 1-6.	2.1	8

#	Article	IF	Citations
19	MFAP5 Loss-of-Function Mutations Underscore the Involvement of Matrix Alteration in the Pathogenesis of Familial Thoracic Aortic Aneurysms and Dissections. American Journal of Human Genetics, 2014, 95, 736-743.	6.2	110
20	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. Current Atherosclerosis Reports, 2014, 16, 439.	4.8	87
21	Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis, 2012, 223, 394-400.	0.8	92
22	Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. Atherosclerosis, 2012, 222, 158-166.	0.8	22
23	TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nature Genetics, 2012, 44, 916-921.	21.4	319
24	Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease). Orphanet Journal of Rare Diseases, 2011, 6, 1.	2.7	116
25	In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9. Journal of Biological Chemistry, 2011, 286, 4257-4263.	3.4	132
26	Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opinion on Therapeutic Patents, 2010, 20, 1547-1571.	5.0	28
27	Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Human Mutation, 2009, 30, 520-529.	2.5	211
28	The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum ofLDLRmutations and role ofPCSK9as a modifier gene. Human Mutation, 2009, 30, E682-E691.	2.5	82
29	Novel mutations of thePCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Human Mutation, 2005, 26, 497-497.	2.5	169
30	Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in PCSK9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1448-1453.	2.4	171
31	NARC-1/PCSK9 and Its Natural Mutants. Journal of Biological Chemistry, 2004, 279, 48865-48875.	3.4	544
32	Heterozygous TGFBR2 mutations in Marfan syndrome. Nature Genetics, 2004, 36, 855-860.	21.4	577
33	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 2003, 34, 154-156.	21.4	2,532